HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer

Inclusion Criteria: * Participants must have histologically confirmed clinical stage II or III ERPR- HER2+ (per CAP criteria) invasive carcinoma of the breast * Medically and surgically appropriate to undergo neoadjuvant chemotherapy with TCH-P Taxotere (docetaxel), Carboplatin, Herceptin (trastuzumab), Perjeta (pertuzumab) regimen followed by standard of care local therapy as determined by their treating physician * Age ≥18 years. * Eastern Cooperative Oncology Group (ECOG) performance status less than 2 * Patients must have normal organ and marrow function as defined below: * leukocytes ≥3,000/μL * absolute neutrophil count ≥1,500/μL * platelets ≥100,000/μL * total bilirubin within normal institutional limits * AST(SGOT)/ALT(SGPT) less than or equal to 2.5 X institutional upper limit of normal * creatinine within normal institutional limits - OR - * creatinine clearance ≥60 mL/min/1.73 m\^2 for patients with creatinine levels above institutional normal * Cardiac ejection fraction within institutional normal limits by either MUGA or ECHO at baseline. * Women of child-bearing potential and their male partners must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Sexually active male participants should use …